Abbott to Carve Out Nutrition Business Into Independent Company

Recent reporting across major financial publications highlights a significant corporate restructuring decision by Abbott. According to coverage from Investor's Business Daily, Yahoo Finance, Barron's, Bloomberg.com, Reuters, and the Wall Street Journal, Abbott has announced its intention to separate its global nutrition business into an independent, publicly traded company. Alongside this major corporate carve-out, the company also disclosed a reduction to its sales growth view for the year 2026. Financial reporting indicates that this nutrition unit has faced notable operational challenges prior to the planned spinoff, framing the division as an embattled part of the broader corporate structure. The unfolding media coverage heavily emphasizes the immediate financial market reaction and the specific structural nature of the transaction.

Outlets such as Investor's Business Daily and Barron's report that Abbott stock fell following the earnings release and the announcement of the spinoff. The Wall Street Journal and Reuters detail the mechanics of the carve-out, pointing to the nutrition unit as a troubled asset being shed from the parent company's portfolio. Bloomberg.com explicitly identifies the division as an embattled business that is responsible for selling baby formula, tying the segment directly to past controversies and operational friction. Contextual details provided across the coverage frame the decision within a choppy third-quarter earnings performance described by Investor's Business Daily. Abbott is executing this separation against a backdrop of lowered expectations for annual performance, specifically reflected in the downward revision of its 2026 sales growth view reported by Reuters.

The impending spinoff represents a major strategic shift for the organization, detaching the nutrition and baby formula operations from the rest of the company's core medical and healthcare business lines as it navigates current market volatility and financial headwinds. Looking ahead, ongoing coverage indicates that market observers will be monitoring the mechanics and timeline of the independent public company formation. While the headlines establish the intent to separate the nutrition business and cut the 2026 sales outlook, coverage does not yet specify the exact date for the completion of the spinoff or the leadership team designated to run the new entity. Stakeholders and investors will continue tracking regulatory filings, stock performance, and further announcements from Abbott regarding the execution of the carve-out strategy.